Effects of Metergoline on Symptoms in Women With Premenstrual Dysphoric Disorder

Authors:
  • PSPeter J. Schmidt
    Peter J. Schmidt
  • MSMark J. Smith
    Mark J. Smith
  • MDMerry A. Danaceau
    Merry A. Danaceau
  • DMDennis L. Murphy
    Dennis L. Murphy
  • DRDavid R. Rubinow
    David R. Rubinow
Publisher website
Google Scholar
Abstract
OBJECTIVE: The authors investigated the role of acute serotonergic modulation in the efficacy of selective serotonin reuptake inhibitors (SSRIs) in women with premenstrual dysphoric disorder. METHOD: Patients with premenstrual dysphoric disorder (whose symptoms had remitted during treatment with fluoxetine) and a group of unmedicated healthy comparison women received the serotonin receptor antagonist metergoline as part of a double-blind, placebo-controlled crossover study. RESULTS: The patients with premenstrual dysphoric disorder experienced a return of symptoms 24 hours after treatment with metergoline but not diphenhydramine (active placebo). The comparison women experienced no changes in mood. CONCLUSIONS: These data support the role of altered serotonergic transmission in the efficacy of SSRI treatment for premenstrual dysphoric disorder.

This publication has 21 references indexed in Scilit: